The Native Antigen Company is part of LGC Clinical Diagnostics - Learn More

0 Items
Select Page

Feline Herpes Virus

Feline viral rhinotracheitis (FVR) is an upper respiratory or pulmonary infection of cats caused by felid alphaherpesvirus 1 (FeHV-1), of the family Herpesviridae. It is also commonly referred to as feline influenza, feline coryza, and feline pneumonia. Epidemiologically, FeHV-1 behaves as a typical alphaherpesvirus where cats which have recovered become latently infected carriers and undergo periodic episodes of virus reactivation, particularly following stress. FVR is very contagious and can cause severe disease, including death from pneumonia in young kittens, although all felidae family members are susceptible to FVR.

Feline Herpes Virus Background

​Feline herpesvirus type 1 (FHV-1; felid herpesvirus 1 (FeHV-1), family Herpesviridae, subfamily Alphaherpesvirinae, genus Varicellovirus) is an important pathogen that causes feline viral rhinotracheitis, a highly infectious upper respiratory tract infection of felids (Davison et al., 2009). There is only one serotype of FHV-1 and it is relatively homogenous genetically (Gaskell et al., 2007). FHV-1 causes half of all respiratory diseases in cats and is the most important of these diseases, being found worldwide. The other important cause of feline respiratory disease is feline calicivirus. Infection with FHV-1 is often fatal to kittens, but adult cats usually survive and exhibit lifelong latency (Povey, 1979; Maes et al., 1984). FHV-1 also causes ocular surface disease, dermatitis, and potentially intraocular disease in cats (Thomasy & Maggs, 2016).

Feline viral rhinotracheitis (FVR) is a typically acute, febrile, contagious disease of felids characterised by sneezing with ocular and nasal discharges. Clinical signs of FVR infection are characterized by lethargy, oculonasal discharge, severe rhinitis, and conjunctivitis (López & Martinson, 2017). The incubation period is 2-4 days, sometimes longer. Mortality is high in young or debilitated cats, but most recover in 7-10 days (Povey, 1979). The disease causes an impairment of pulmonary defense mechanisms predisposing cats to secondary bacterial pneumonia or to a coinfection with feline calicivirus. FeHV-1 targets both respiratory epithelial cells and pneumocytes and pneumonia is the consequence of continuous cell-to-cell viral spread from the upper airways via the trachea into the lungs. It is likely that FeHV-1-infected cells die primarily via apoptosis, following loss of cell-to-cell contact, rounding, and detachment (Monne Rodriguez et al., 2017). The virus can also remain latent in ganglia. The vast majority of cats that recover from FVR become carriers and shed FeHV-1, either spontaneously or following stress.

Antiviral drugs developed for the treatment of humans infected with herpesviruses have been used to treat cats infected with FHV-1, with varying degrees of success (Thomasy & Maggs, 2016). Vaccines that protect against feline viral rhinotracheitis and feline calicivirus are also available.


  • Alfonso López, Shannon A. Martinson, Feline Viral Rhinotracheitis. In Pathologic Basis of Veterinary Disease (Sixth Edition), 2017.
  • Davison et al. (2009). The order Herpesvirales. Arch. Virol. 154:171–177.
  • Gaskell et al. (2007). Feline herpesvirus. Vet Res. 38(2):337–354.
  • Maes et al. (1984). Immunogenic proteins of feline rhinotracheitis virus. J. Virol. 51:259–262.
  • Monne Rodriguez et al. (2017). Feline Herpesvirus Pneumonia: Investigations Into the Pathogenesis. Vet Pathol. 54(6):922–932.
  • Povey R.C. (1979). A review of feline viral rhinotracheitis (feline herpesvirus I infection) Comp. Immunol. Microbiol. Infect. Dis. 2:373–387.
  • Thomasy SM, Maggs DJ. (2016). A review of antiviral drugs and other compounds with activity against feline herpesvirus type 1. Vet Ophthalmol. 19 Suppl 1(Suppl 1):119–130.

Feline Herpes Virus Antigens

The Native Antigen Company is pleased to provide a native feline herpes virus antigen for all of your assay development and research needs.


Check out our FAQ section for answers to the most frequently asked questions about our website and company.

Monkeypox; 3 months on

It has been 3 months since a new, unusually widespread outbreak of Monkeypox was first identified. What was normally a virus confined to limited infections in the West African continent is becoming a global health concern.   What have we learned about this virus...

COVID-19 Underlines the Need for Universal Vaccines

This article was originally published on Clinical Lab Manager. In recent history, humanity has witnessed numerous emerging viral diseases, including the SARS, MERS, and SARS-2 coronaviruses, as well as HIV, Zika, Ebola, and H1N1 and H3N2 influenza. None have tested...

Tick-Borne Diseases: The Need for Integrated Approaches to Human-Animal Diagnosis

This article has been published in Volume 8, Issue 3 of International Animal Health Journal. Ticks are responsible for a diverse group of neglected, and rapidly expanding diseases, affecting humans, companion animals and livestock. A growing understanding of tick-host...

The Continued Challenges of Flavivirus Serology

This article was originally published on the Science Advisory Board. Flaviviruses are a genus of positive-sense RNA viruses, largely transmitted by mosquito and tick vectors that cause infections, including yellow fever, dengue, the Zika virus, West Nile virus,...

The Role of Serology in Tracking COVID-19 Mutations

This article was originally published on Clinical Lab Products. As SARS-CoV-2 began its global proliferation in early 2020, scientists hastened to investigate its biology, develop diagnostic tests, and design candidate vaccines, marking one of the most...

Get in Touch

We sometimes send exclusive information and offers to our customers - please let us know if you are happy to receive these

13 + 1 =